OBJECTIVES: The purpose of this study was to examine the incidence of nuisance bleeding after AMI and its impact on QOL. BACKGROUND:Prolonged dual antiplatelet therapy (DAPT) is recommended after acute myocardial infarction (AMI) to reduce ischemic events, but it is associated with increased rates of major and minor bleeding. The incidence of even lesser degrees of post-discharge "nuisance" bleeding with DAPT and its impact on quality of life (QOL) are unknown. METHODS: Data from the 24-center TRIUMPH (Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status) study of 3,560 patients, who were interviewed at 1, 6, and 12 months after AMI, were used to investigate the incidence of nuisance bleeding (defined as Bleeding Academic Research Consortium type 1). Baseline characteristics associated with "nuisance" bleeding and its association with QOL, as measured by the EuroQol 5 Dimension visual analog scale, and subsequent re-hospitalization were examined. RESULTS: Nuisance (Bleeding Academic Research Consortium type 1) bleeding occurred in 1,335 patients (37.5%) over the 12 months after AMI. After adjusting for baseline bleeding and mortality risk, ongoing DAPT was the strongest predictor of nuisance bleeding (rate ratio [RR]: 1.44, 95% confidence interval [CI]: 1.17 to 1.76 at 1 month; RR: 1.89, 95% CI: 1.35 to 2.65 at 6 months; and RR: 1.39, 95% CI: 1.08 to 1.79 at 12 months; p < 0.01 for all comparisons). Nuisance bleeding at 1 month was independently associated with a decrement in QOL at 1 month (-2.81 points on EuroQol 5 Dimension visual analog scale; 95% CI: 1.09 to 5.64) and nonsignificantly toward higher re-hospitalization (hazard ratio: 1.20; 95% CI: 0.95 to 1.52). CONCLUSIONS:Nuisance bleeding is common in the year after AMI, associated with ongoing use of DAPT, and independently associated with worse QOL. Improved selection of patients for prolonged DAPT may help minimize the incidence and adverse consequences of nuisance bleeding.
RCT Entities:
OBJECTIVES: The purpose of this study was to examine the incidence of nuisance bleeding after AMI and its impact on QOL. BACKGROUND: Prolonged dual antiplatelet therapy (DAPT) is recommended after acute myocardial infarction (AMI) to reduce ischemic events, but it is associated with increased rates of major and minor bleeding. The incidence of even lesser degrees of post-discharge "nuisance" bleeding with DAPT and its impact on quality of life (QOL) are unknown. METHODS: Data from the 24-center TRIUMPH (Translational Research Investigating Underlying Disparities in Acute Myocardial InfarctionPatients' Health Status) study of 3,560 patients, who were interviewed at 1, 6, and 12 months after AMI, were used to investigate the incidence of nuisance bleeding (defined as Bleeding Academic Research Consortium type 1). Baseline characteristics associated with "nuisance" bleeding and its association with QOL, as measured by the EuroQol 5 Dimension visual analog scale, and subsequent re-hospitalization were examined. RESULTS: Nuisance (Bleeding Academic Research Consortium type 1) bleeding occurred in 1,335 patients (37.5%) over the 12 months after AMI. After adjusting for baseline bleeding and mortality risk, ongoing DAPT was the strongest predictor of nuisance bleeding (rate ratio [RR]: 1.44, 95% confidence interval [CI]: 1.17 to 1.76 at 1 month; RR: 1.89, 95% CI: 1.35 to 2.65 at 6 months; and RR: 1.39, 95% CI: 1.08 to 1.79 at 12 months; p < 0.01 for all comparisons). Nuisance bleeding at 1 month was independently associated with a decrement in QOL at 1 month (-2.81 points on EuroQol 5 Dimension visual analog scale; 95% CI: 1.09 to 5.64) and nonsignificantly toward higher re-hospitalization (hazard ratio: 1.20; 95% CI: 0.95 to 1.52). CONCLUSIONS: Nuisance bleeding is common in the year after AMI, associated with ongoing use of DAPT, and independently associated with worse QOL. Improved selection of patients for prolonged DAPT may help minimize the incidence and adverse consequences of nuisance bleeding.
Authors: Roxana Mehran; Sunil V Rao; Deepak L Bhatt; C Michael Gibson; Adriano Caixeta; John Eikelboom; Sanjay Kaul; Stephen D Wiviott; Venu Menon; Eugenia Nikolsky; Victor Serebruany; Marco Valgimigli; Pascal Vranckx; David Taggart; Joseph F Sabik; Donald E Cutlip; Mitchell W Krucoff; E Magnus Ohman; Philippe Gabriel Steg; Harvey White Journal: Circulation Date: 2011-06-14 Impact factor: 29.690
Authors: Itsik Ben-Dor; Rebecca Torguson; Mickey Scheinowitz; Yanlin Li; Cedric Delhaye; Kohei Wakabayashi; Gabriel Maluenda; Asmir I Syed; Sara D Collins; Manuel A Gonzalez; Michael A Gaglia; Zhenyi Xue; Kimberly Kaneshige; Lowell F Satler; William O Suddath; Kenneth M Kent; Augusto D Pichard; Ron Waksman Journal: Am Heart J Date: 2010-05 Impact factor: 4.749
Authors: Steven R Steinhubl; Peter B Berger; J Tift Mann; Edward T A Fry; Augustin DeLago; Charles Wilmer; Eric J Topol Journal: JAMA Date: 2002-11-20 Impact factor: 56.272
Authors: Suzanne V Arnold; Paul S Chan; Philip G Jones; Carole Decker; Donna M Buchanan; Harlan M Krumholz; P Michael Ho; John A Spertus Journal: Circ Cardiovasc Qual Outcomes Date: 2011-07
Authors: Jaya Chandrasekhar; Benjamin Hibbert; Michael Froeschl; Derek So; Roxana Mehran; Michel Le May Journal: Eur J Clin Pharmacol Date: 2015-10-09 Impact factor: 2.953
Authors: Ernest Spitzer; Martina Frei; Serge Zaugg; Susanne Hadorn; Henning Kelbaek; Miodrag Ostojic; Andreas Baumbach; David Tüller; Marco Roffi; Thomas Engstrom; Giovanni Pedrazzini; Vladan Vukcevic; Michael Magro; Ran Kornowski; Thomas F Lüscher; Clemens von Birgelen; Dik Heg; Stephan Windecker; Lorenz Räber Journal: J Am Heart Assoc Date: 2017-08-05 Impact factor: 5.501
Authors: Mohammed Qintar; Adnan K Chhatriwalla; Suzanne V Arnold; Fengming Tang; Donna M Buchanan; Ali Shafiq; Yashashwi Pokharel; Dave deBronkart; Javed M Ashraf; John A Spertus Journal: Catheter Cardiovasc Interv Date: 2017-02-07 Impact factor: 2.692
Authors: Carole Decker; Linda Garavalia; Brian Garavalia; Elizabeth Gialde; Robert W Yeh; John Spertus; Adnan K Chhatriwalla Journal: Am Heart J Date: 2016-05-26 Impact factor: 4.749
Authors: Praneet K Sharma; Adnan K Chhatriwalla; David J Cohen; Jae-Sik Jang; Paramdeep Baweja; Kensey Gosch; Philip Jones; Richard G Bach; Suzanne V Arnold; John A Spertus Journal: Catheter Cardiovasc Interv Date: 2016-04-01 Impact factor: 2.692
Authors: Amit P Amin; Tracy Y Wang; Lisa McCoy; Richard G Bach; Mark B Effron; Eric D Peterson; David J Cohen Journal: J Am Coll Cardiol Date: 2016-01-05 Impact factor: 24.094
Authors: Adnan K Chhatriwalla; Carole Decker; Elizabeth Gialde; Delwyn Catley; Kathy Goggin; Katie Jaschke; Philip Jones; Dave deBronkart; Tony Sun; John A Spertus Journal: Circ Cardiovasc Qual Outcomes Date: 2019-02